Heron Therapeutics Inc vs Peloton Interactive Inc — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Peloton Interactive Inc trades at $5.6 (market cap $2.42B). The key difference: Peloton Interactive Inc is far larger — about 38.2× Heron Therapeutics Inc's market cap, and Peloton Interactive Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | PTON | |
|---|---|---|
Market Cap | $63.41M | $2.42B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $9.00 |
52-Week Low | $0.32 | $3.71 |
Enterprise Value | $161.31M | $2.92B |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Peloton Interactive (PTON) trades at $5.68, up 3.18% with a bearish technical signal despite recent earnings beat. The company achieved its first annual net profit in fiscal 2026 with $63M net income, though revenue declined to $2.4B. Valuation metrics show a P/E of 40.54 and P/S of 1.01, while negative shareholder equity of -$413.7M reflects historical losses. Recent news highlights profitability progress but concerns about subscriber declines and conservative 2027 guidance.
PTON presents a turnaround story with improving profitability but faces significant revenue headwinds. The stock offers potential upside if subscriber stabilization occurs, though high debt levels and competitive pressures pose substantial risks. Analyst consensus is divided with 50% buy ratings, suggesting cautious optimism amid ongoing business transformation challenges.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →